1058722-46-5

Basic information

• Product Name: 5-(HydroxyMethyl)-N-[4-(trifluoroMethyl)phenyl]-4-isoxazolecarboxaMide
• Synonyms: 5-(HydroxyMethyl)-N-[4-(trifluoroMethyl)phenyl]-4-isoxazolecarboxaMide;5-Hydroxy LeflunoMide (Metabolite M2)
• CAS NO: 1058722-46-5
• Molecular Formula: C12H9F3N2O3
• Molecular Weight: 286.2066696
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics, Heterocycles, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1058722-46-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(HydroxyMethyl)-N-[4-(trifluoroMethyl)phenyl]-4-isoxazolecarboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(HydroxyMethyl)-N-[4-(trifluoroMethyl)phenyl]-4-isoxazolecarboxaMide(1058722-46-5)
• EPA Substance Registry System: 5-(HydroxyMethyl)-N-[4-(trifluoroMethyl)phenyl]-4-isoxazolecarboxaMide(1058722-46-5)

Safety Data

• Hazardous Substances Data: 1058722-46-5(Hazardous Substances Data)

Usage

Uses

5-Hydroxy Leflunomide is a metabolite of Leflunomide (L322750).

Upstream product

• 136995-25-0 5-Methoxymethyl-isoxazole-4-carboxylic acid (4-trifluoromethyl-phenyl)-amide 
• 127958-23-0 methyl 2-[(dimethylamino)methylene]-4-methoxy-3-oxobutanoate 
• 134541-08-5 5-(methoxymethyl)isoxazole-4-carboxylic acid 
• 134540-99-1 methyl 5-(methoxymethyl)isoxazole-4-carboxylate 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.